Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next
Insmed shares rose 5% to $174.90 Friday after a steep Thursday drop, following news that its Phase 2b BiRCh trial in CRSsNP missed endpoints and the program was discontinued. Trading volume spiked Thursday as shares fell 16%. The rebound came as analysts reiterated Buy ratings, citing Insmed’s bronchiectasis franchise and respiratory pipeline. The stock remains below its 52-week high of $212.75.